The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor
(HGF/SF) have become leading candidates for targeted cancer therapies. Inappropriate c …

Studies on signal transduction pathways have generated various promising molecular
targets for therapeutic inhibition in cancer therapy. Receptor tyrosine kinases represent an …

On binding to the cell surface receptor tyrosine kinase (TK) known as c-Met, hepatocyte
growth factor (HGF) stimulates mitogenesis, motogenesis, and morphogenesis in a wide …

In a recent issue of Molecular Cancer Therapeutics, Burgess and colleagues (1) give a
detailed biochemical and functional characterization of AMG 102, a fully humanized …

c-MET is the membrane receptor for hepatocyte growth factor (HGF), also known as scatter
factor or tumor cytotoxic factor, a mitogenic growth factor for hepatocytes. HGF is mainly …

A wide variety of human malignancies exhibit sustained c-Met stimulation, overexpression,
or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid …

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib,
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …

Receptor tyrosine kinases are a group of molecules that can enhance cellular proliferation,
cell motility and migration, and eventual metastasis. c-Met receptor tyrosine kinase has a …

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate
multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This …

The scatter factor/hepatocyte growth factor (HGF)-c-Met axis is involved in the malignant
phenotype of various tumor types via activation of a wide range of autocrine and paracrine …